Oncology News | pharmaphorum

News

AZ reportedly mulls biggest-ever pharma merger with Gilead

Almost exactly six years ago AstraZeneca managed to convince investors to reject a takeover bid from Pfizer – and now the UK pharma is reportedly planning its own mega-merger with Gilead. <

News

AZ to work with Accent on RNA-modifying protein tech in canc...

AstraZeneca is to work with US biotech Accent Therapeutics on therapies targeting RNA-modifying proteins (RMPs) for treatment of cancer.

News

Sanofi's multiple myeloma drug approved in EU

Sanofi’s new multiple myeloma drug Sarclisa (isatuximab) has been approved in the EU for relapsed/refractory disease, taking on Johnson & Johnson’s well-established blockbuster Darzalex

News

Roche’s Tecentriq/Avastin combo gets liver cancer nod

The FDA has approved Roche’s combination of its Tecentriq and Avastin drugs in previously-untreated hepatocellular carcinoma (HCC) – the most common form of liver cancer.

News

David Loew swaps Sanofi’s top vaccine job for CEO role at Ip...

Sanofi had no sooner announced the departure of David Loew, its head of vaccines, before he surfaced as the new chief executive of French specialty drugmaker Ipsen, taking over

News

AZ nabs a positive study for Imfinzi plus tremelimumab in li...

After a long run of trial disappointments, AstraZeneca is celebrating a win for its immuno-oncology combination of Imfinzi plus tremelimumab in advanced liver cancer.

AZ reportedly mulls biggest-ever pharma merger with Gilead

AZ to work with Accent on RNA-modifying protein tech in canc...

Sanofi's multiple myeloma drug approved in EU

Roche’s Tecentriq/Avastin combo gets liver cancer nod

David Loew swaps Sanofi’s top vaccine job for CEO role at Ip...

AZ nabs a positive study for Imfinzi plus tremelimumab in li...

Simple blood test could aid in global TB fight

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks